NDAORALCAPSULE, EXTENDED RELEASE
Lifecycle
Pre-Launch
Data completeness
3/8 — Basic
ISORDIL (isosorbide dinitrate) by Thayer Medical is clinical pharmacology the principal pharmacological action of isosorbide dinitrate is relaxation of vascular smooth muscle and consequent dilatation of peripheral arteries and veins, especially the latter. Approved for heart failure, diabetes.
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ISORDIL (isosorbide dinitrate) is an oral extended-release nitrate vasodilator that relaxes vascular smooth muscle to reduce preload and afterload on the heart. It is indicated for heart failure and diabetes management, working primarily through coronary artery dilation and peripheral vascular pooling to decrease cardiac workload.
$68,000Part D
Pre-LaunchPre-launch stage indicates small initial team with significant growth potential as the product enters market; commercial infrastructure is being built.
Mechanism of Action
CLINICAL PHARMACOLOGY The principal pharmacological action of isosorbide dinitrate is relaxation of vascular smooth muscle and consequent dilatation of peripheral arteries and veins, especially the latter. Dilatation of the veins promotes peripheral pooling of blood and decreases venous return to…
Worked on ISORDIL at Thayer Medical? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.